González-Calle V, Rodríguez-Otero P, Sureda A, de Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos M-V. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study. haematol [Internet]. 2024Jul.1 [cited 2024Nov.27];109(7):2219-28. Available from: https://haematologica.org/article/view/haematol.2023.284089